In November 2014, Gordon learned that he had a malignant tumor in his colon. Over the next four years, Gordon underwent surgery and chemotherapy, which put him into two two-year remissions. In early 2018, the cancer came back again, this time having also spread to the abdomen, liver, lung, and bone. Gordon enrolled in a clinical trial where he received pembrolizumab (Keytruda®). While the treatment showed early promise, CT scans later that year indicated tumor growth. Having exhausted his available treatment options in Montreal, Gordon sought a second opinion at UCSD Moores Cancer Center in San Diego. Genetic testing indicated that Gordon might respond to treatment with a combination of the immunotherapies nivolumab (Opdivo®) and ipilimumab (Yervoy®). After three rounds of treatment, a CT scan showed substantial reduction in the cancer. As a result of the immunotherapy combination, Gordon was able to reduce his pain medication and live an active life again. Treatment ended in the summer of 2020, having resulted in the eradication of all of the cancer save for a resistant area in the sigmoid colon. In the spring of 2021, Gordon underwent surgery to remove the remaining disease and create a permanent ostomy. His most recent scan confirmed no evidence of disease – an incredible accomplishment after a very long journey.